A potential causal effect between SGLT2 inhibition and an elevated risk of cervical cancer (beta: 3.241 [0.855, 5.627], P = 0.008) and lymphoid leukemia (beta: 4.126 [0.383, 7.868], P = 0.031) was observed, with non-significant heterogeneity or pleiotropy supporting these findings (Figure 3, Supplementary Table S4). The gene discussed is SLC5A2; the disease is cervical carcinoma.